N,N'-bis-(4-iodo-phenyl)-guanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N'-bis-(4-iodo-phenyl)-guanidine
• 英文别名: N,N'-Bis-(4-jod-phenyl)-guanidin；1,2-Bis(4-iodophenyl)guanidine
• 化学式: C₁₃H₁₁I₂N₃
• 分子量: 463.059
• InChiKey: VRTSVSOJRVUFCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  对碘苯胺 在 对甲苯磺酸 、 N,N-二异丙基乙胺 、 氯苯 作用下， 以 四氢呋喃 为溶剂， 反应 48.67h， 生成 N,N'-bis-(4-iodo-phenyl)-guanidine
  参考文献：
  名称：

  Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer

  摘要：

  Prostate cancer is the most frequently diagnosed malignancy and the leading cause of cancer related death in men. First line therapy for disseminated disease relies on androgen deprivation, leveraging the addiction of these tumors on androgens for both growth and survival. Treatment typically involves antagonizing the androgen receptor (AR) or blocking the synthesis of androgens. Recurrence is common and within 2-3 years patients develop castration resistant tumors that become unresponsive to AR-axis targeted therapies. In order to provide a more effective treatment, we are utilizing an approach that targets a key scaffolding protein, Sigma1 (also known as sigma-1 receptor), a unique 26-kilodalton integral membrane protein that is critical in stabilizing the AR. Herein we report on a new series of Sigmal compounds for lead optimization derived from a hybrid pharmacophore approach. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.03.030

文献信息

• Hofmann,A.W., Justus Liebigs Annalen der Chemie, 1848, vol. 67, p. 152
  作者：Hofmann,A.W.

  DOI：——

  日期：——
• Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer
  作者：Joseph M. Salvino、Yellamelli V.V. Srikanth、Rongliang Lou、Halley M. Oyer、Nan Chen、Felix J. Kim

  DOI：10.1016/j.bmcl.2017.03.030

  日期：2017.5

  Prostate cancer is the most frequently diagnosed malignancy and the leading cause of cancer related death in men. First line therapy for disseminated disease relies on androgen deprivation, leveraging the addiction of these tumors on androgens for both growth and survival. Treatment typically involves antagonizing the androgen receptor (AR) or blocking the synthesis of androgens. Recurrence is common and within 2-3 years patients develop castration resistant tumors that become unresponsive to AR-axis targeted therapies. In order to provide a more effective treatment, we are utilizing an approach that targets a key scaffolding protein, Sigma1 (also known as sigma-1 receptor), a unique 26-kilodalton integral membrane protein that is critical in stabilizing the AR. Herein we report on a new series of Sigmal compounds for lead optimization derived from a hybrid pharmacophore approach. (C) 2017 Elsevier Ltd. All rights reserved.